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Abstract: Numerous studies have demonstrated the ability of isoflurane conditioning to provide
multifaceted protection against aneurysmal subarachnoid hemorrhage (SAH)-associated delayed
cerebral ischemia (DCI); however, preclinical studies have not yet examined whether other commonly
used inhalational anesthetics in neurological patients such as sevoflurane or desflurane are also
protective against SAH-induced neurovascular deficits. We therefore sought to identify the potential
for sevoflurane and desflurane conditioning to protect against DCI in an endovascular perforation
mouse model of SAH. Neurological function was assessed daily via neuroscore. Large artery
vasospasm and microvessel thrombosis were assessed three days after SAH or sham surgery. Four
groups were examined: Sham, SAH + room air, SAH + 2% Sevoflurane, and SAH + 6% Desflurane.
For the SAH groups, one hour after surgery, mice received 2% sevoflurane, 6% desflurane, or room
air for one hour. We found that conditioning with sevoflurane or desflurane attenuated large artery
vasospasm, reduced microvessel thrombosis, and improved neurologic function. Given their frequent
clinical use and strong safety profile in patients (including those with SAH), these data strongly
support further studies to validate these findings in preclinical and clinical studies and to elucidate
the mechanisms by which these agents might be acting.
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1. Introduction
Aneurysmal subarachnoid hemorrhage (SAH) affects approximately 500,000 people/year worldwide [1] and accounts for over 70% of all forms of subarachnoid hemorrhage [2]. Roughly 30% of these patients die and 50% of survivors experience substantial
deficits [2,3]. Notably, these poor outcomes are disproportionately influenced by Delayed
Cerebral Ischemia (DCI), which is a form of clinical deterioration that manifests multiple
days following the initial aneurysmal rupture [4,5]. DCI occurs in approximately 30% of
SAH patients [2,6–8] and is strongly associated with increased patient mortality [7,8]. While
modern pharmacological [9] and neurointerventional [10] treatments offer options for addressing certain aspects of DCI, a robustly effective preventative therapy remains elusive.
Comprehensive protection against DCI requires consideration of its diverse neurovascular and neuroelectric underpinnings [4]. Phenomena such as large artery vasospasm,
thrombotic events within the microvasculature, and spreading depolarizations have been
implicated in the pathophysiology of DCI [4]. Though seemingly disparate, such phenomena may be schematized as diverse manifestations of a shared biological heritage.
This understanding of DCI pathogenesis suggests that comprehensive protection can be
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attained by targeting fundamental biomolecular and cellular roots, rather than individual
symptomatic manifestations.
Controlled exposure to a noxious stimulus following an acute injury can be used to
induce a variety of protective biomolecular and cellular adaptations [11]. This innovative
therapeutic approach, termed conditioning, provides an avenue for exploring comprehensive preventative therapies for DCI [11]. Numerous recent studies, including our own, have
demonstrated that isoflurane can offer this form of protection against various DCI-related
pathologies [12–16]. The potential for isoflurane conditioning to protect against DCI is
noteworthy, given its existing use in the clinical setting. However, it is also important to
note that isoflurane is considered less desirable than the other commonly used inhalational
anesthetics in the clinic, including sevoflurane and desflurane [17–26]. Specifically, the solubility of both sevoflurane and desflurane anesthetics in blood is lower, resulting in faster
emergence from anesthetic, allowing a more immediate post-operative neurological examination. [21–23]. Therefore, findings showing a potential DCI protection for sevoflurane
or desflurane may be as, if not more, readily translated into standard-of-care paradigms
for SAH care. Additionally, such studies would help inform ongoing comparisons between anesthetic treatments (e.g., inhalational vs. intravenous) and thereby enable optimal
anesthetic management for SAH patients.
To the best of our knowledge, no published investigation has prospectively investigated the pathophysiological basis and causative relationships (if any) between sevoflurane
or desflurane conditioning and protection against SAH-induced DCI. Through this study,
we therefore seek to systematically elucidate whether exposure to sevoflurane or desflurane
following SAH can attenuate DCI and improve neurological outcomes.
2. Methods
2.1. Institutional Approval
These mouse-model experiments were conducted following obtainment of institutional approval and authorization (Institution: Washington University in Saint Louis,
Committee: Institutional Animal Care and Use Committee, Protocol: 20180080, Effective:
22 July 2019).
2.2. Experimental Design and Animals
Adult male mice of the C57BL/6J wild-type strain (The Jackson Laboratory, Bar
Harbor, ME, USA) were utilized in these investigations. At the time of experimentation,
all mice were roughly 12 weeks of age. These prospective experiments were conducted
with four treatment groups. Two groups possessed the experimental variables of interest:
SAH + Sevoflurane and SAH + Desflurane. Sham and SAH + room air treatment groups
were included as procedural and conditioning controls, respectively. Mice were randomly
assigned to one of these four experimental treatment groups. Experiments were blinded to
the person who conducted the neurological examination. All surgeries were performed
by an experienced animal surgeon. For the duration of the experiments and whilst within
their home cages, all mice had unrestricted access to food, water, and room air. Figure 1
represents the experimental design of the study.
2.3. Murine Model of Aneurysmal Subarachnoid Hemorrhage
Our method for experimentally inducing SAH in mice was adapted from prior work
in this domain [12–15]. In this established model, a suture is inserted into the lumen of
the left external carotid artery and progressed cranially until the point at which the left
internal carotid artery (L-ICA) branches into the left middle cerebral artery (L-MCA) and
left anterior cerebral artery. At the region of this juncture, the suture tip is used to pierce
the vessel wall, causing hemorrhage. For control (sham) surgical procedures, the suture
tip is similarly maneuvered through the carotid arterial vasculature; however, the tip is
withdrawn upon encountering the L-ICA bifurcation aforementioned. SAH induction in
the mice was confirmed by the presence of apnea immediately after the suture perforation
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and by the presence of blood on the ventral surface of brain in SAH animals during the
animal sacrifice.

Figure 1.
design
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study.
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hemorrhage.
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2.5. Anesthetic Exposure to Sevoflurane or Desflurane

As in other investigations of inhalational anesthetic exposure [12–15], mice in the an-
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2.6. Imaging of the Left Middle Cerebral Artery
On the 3rd day following SAH (Day 3), mice were sacrificed. A modified version
of the procedure detailed by Aum et al. [29] was adapted and implemented to stain the
cerebral vasculature while controlling for perfusion time and pressure. Key events within
our procedure included: (1) clearance of endogenous blood through vascular perfusion
with a solution containing Heparin and Phosphate-Buffered Saline, (2) vascular fixation
with a 10% formalin solution, and (3) vascular staining with a solution containing 5-(and-6)Carboxy-X-rhodamine, succinimidyl ester. Techniques utilized for fluorescence microscopy
imaging and analysis of the cerebral vasculature were similar to those described in prior
publications [12–15]. Following extraction of the vessel-casted mouse brain, imaging was
performed using a microscope (Nikon Eclipse ME600, Nikon, Tokyo, Japan), fluorescent
lighting (X-CiteTM 120PC, EXFO, Quebec City, QC, Canada), and digital camera (Lumenera
Infinity 3S, Lumenera Corporation, Ottawa, ON, Canada). Images were acquired and
saved using image-processing software (MetaMorph, Molecular Devices, San Jose, CA,
USA). The smallest L-MCA diameter within 1 mm of this vessel’s origin was subsequently
quantified. The resultant value represents our numerical measure for vasospasm.
2.7. Fibrinogen Level Assessment
To quantify the degree of thrombosis within the cerebral microcirculation, fibrinogen
levels (measured as percent coverage) were assessed through immunofluorescence. For
this procedure, five brains from each of the four experimental treatment groups were arbitrarily selected for fibrinogen quantification. The immunofluorescent staining and imaging
procedure utilized is detailed by Liu et al. [15]. To briefly summarize, key steps include:
(1) coronal sectioning (50 µM thickness) of brain specimen; (2) incubation in a blocking buffer; (3) incubation in rabbit anti-fibrinogen antibody (1:3000, Abcam, Cambridge,
MA, USA); (4) incubation in donkey anti-rabbit secondary antibody (1:2000, Invitrogen
Waltham, MA, USA), and (5) imaging (NanoZoomer 2.0-HT, Hamamatsu Photonics K.K,
Hamamatsu, Japan).
2.8. Statistical Analysis
Statistical analysis was performed on GraphPad Prism 7 (GraphPad Prism 7, GraphPad Software, San Diego, CA, USA). To analyze vasospasm and microvessel thrombosis
results, ANOVA (one-way) and a post hoc Student–Newman–Keuls (SNK) statistical test
were utilized. For comparison of neuroscore results, a two-factor repeated-measures
ANOVA was coupled with the post hoc SNK test. The threshold for statistical significance
is a resultant p-value less than 0.05.
3. Results
3.1. Final Sample Sizes and Exclusions
A total of 66 mice were originally obtained for these experiments. Exclusions were
made on the basis of either early mortality or inability to obtain clear results: three mice
were excluded due to mortality prior to sacrifice and an additional two mice were excluded
due to unclear neurovascular imaging results. Therefore, a total of 61 mice were utilized
for examining the vasospasm and neurologic function, with the final sample size of Sham
(n = 14), SAH + room air (n = 15), SAH + Sevoflurane (n = 14), and SAH + Desflurane
(n = 18). SAH was noted in the animals that underwent SAH procedure and no blood was
seen in the sham group. For microvascular thrombosis assessments, five mouse brains were
arbitrarily selected from each of the four aforementioned treatment groups. Final analyzed
sample sizes are as follows: Sham (n = 4), SAH + room air (n = 5), SAH + Sevoflurane
(n = 5), and SAH + Desflurane (n = 5). One exclusion was made for an abnormal outlier in
the sham group.
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erature indicating inhalational anesthetics as a conditioning agent class provide robust
neurovascular protection in SAH; [12–16] (2) they show that the much more commonly
used inhalational anesthetics, sevoflurane and desflurane, provide potent and multifaceted
protection against DCI in SAH, very similar to that previously reported with isoflurane
conditioning; [12–16] and (3) they provide preclinical support for the recently reported
protective effect of sevoflurane and desflurane against angiographic vasospasm and DCI in
SAH patients [30–32]. Given the pharmacologic advantages of sevoflurane and desflurane
over isoflurane (e.g., the blood–gas and the oil–gas partition coefficient of isoflurane is
significantly larger than that of sevoflurane and desflurane [25,26]—both of which lead
to prolonged clinical emergence [19–21] from general anesthesia that can confound postprocedure neurological assessment), the very high usage rate of sevoflurane and desflurane
in neurosurgical patients, and the proven safety track record of desflurane and sevoflurane
in a wide variety of patients, the results from our study have relevant and meaningful
implications for the care of SAH patients that deserve further investigation.
4.1. Sevoflurane Conditioning in SAH
To the best of our knowledge, there are no preclinical studies in the published literature that examine whether sevoflurane conditioning is capable of providing protection
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against DCI. The results of our study showing that a clinically relevant dose of sevoflurane
affords protection against vasospasm and microvessel thrombosis and improves neurologic
function is novel and further supports the use of inhalational anesthetic conditioning
approaches in DCI prevention. It is important to note that sevoflurane may have numerous
additional clinical advantages as an inhalational anesthetic. First, sevoflurane has been
shown to cause less respiratory irritation than either of the other inhalational anesthetics being discussed [24]. Second, sevoflurane may possess benefits over isoflurane with regards
to blood flow and vascular autoregulation [22]. Third, recent rodent-model studies suggest
that sevoflurane also mitigates another form of secondary brain injury caused by SAH,
namely early brain injury (EBI) [33–35]. Sorar et al. noted that one-hour exposures to either
1.5% or 3% sevoflurane initiated one hour after SAH in a mouse endovascular perforation
model protected against cerebral edema and neuronal apoptosis and improved neurobehavioral outcomes at 24 h post SAH [33]. Altay et al. found that 3% sevoflurane and 2%
isoflurane offered comparable degrees of prevention against neuronal apoptosis and cerebral edema, leading to improved neurological function [34]. Both studies suggested that the
EBI protection by inhalational anesthetics were mediated through the sphingosine kinase
pathway. A more recent study by Beck-Schimmer et al. found that sevoflurane sedation
for 4 h initiated 15 min post SAH using a rat endovascular perforation model attenuated
cerebral edema by stabilizing the adherens junction [35]. Future preclinical studies should
aim to elucidate the mechanism and therapeutic window of sevoflurane conditioning.
Additionally, it remains to be determined whether sevoflurane’s protective abilities extend
to long-term neurologic outcomes and to other features of DCI pathophysiology.
4.2. Desflurane Conditioning in SAH
Several clinical studies, including our own, have suggested that desflurane exposure during aneurysm repair in SAH patients is associated with reduced incidence of
angiographic vasospasm and DCI [30,31,36]. However, to date, no published preclinical
studies have prospectively investigated this relationship. Our novel preclinical findings
showing desflurane’s ability to afford strong protection against SAH-induced DCI provide
further salient insights that support previous clinical data. Further studies are warranted to
investigate the therapeutic window, underlying mechanisms, and long-term outcomes of
desflurane conditioning. Moreover, it is imperative to investigate whether, like sevoflurane
and isoflurane [34], desflurane might also provide protection against EBI.
4.3. Anesthetic Conditioning and Microvessel Thrombosis
Multiple neurovascular features have been implicated in DCI pathophysiology [4,5].
Relative to large-vessel vasospasm, the phenomenon of microvascular thrombus formation
has been a recent addition to our understanding of DCI [37]. While a protective role
against microvessel thrombosis in a DCI-specific setting has been proposed for isoflurane
conditioning [12,15], our findings with sevoflurane and desflurane provide novel evidence
that inhalational anesthetics as a class might be able to protect against DCI-associated microvessel thrombosis. While multiple features of the thrombus-forming cascade have been
identified and proposed [37], it remains unclear as to how these inhalational anesthetics
might be exerting their effects on the cerebral microvasculature. Further preclinical studies
aiming to elucidate how the different anesthetic agents are acting at the molecular level
will enable the discovery of novel targets for DCI therapeutics and enable a more practical
understanding of microvessel thrombosis.
5. Conclusions
Our data support sevoflurane and desflurane as conditioning agents capable of offering robust DCI protection after SAH. Given the existing use of these agents in contemporary
anesthetic practice and the necessity for multifaceted protection in SAH, our findings possess both translational potential and clinical impact. Investigations aiming to validate and
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further elucidate these roles are warranted to empower incorporation into standard-of-care
DCI prevention paradigms.
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